Milestone Pharmaceuticals Inc. (MIST)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. This filer's financial year end could not be read from its revenue history, so quarters are labelled by the calendar. Amounts in USD.

Revenue Quarterly

0 200K 400K 600K Q1 '25: 0 Q2 '25: 0 Q1 '26: 238K Q2 '26: 559K Q1 '25 Q2 '25 Q1 '26 Q2 '26

Gross Profit Quarterly

0 200K 400K 600K Q1 '25: 0 Q2 '25: 0 Q1 '26: 224K Q2 '26: 527K Q1 '25 Q2 '25 Q1 '26 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Quarterly

-27M -18M -9M 0 9M 18M 27M Q3 '21: -14.3M Q4 '21: -16.9M Q1 '22: -14M Q2 '22: -16.8M Q3 '22: -15M Q4 '22: -13.8M Q1 '23: -15.5M Q2 '23: -16.4M Q3 '23: -15.4M Q4 '23: -13.8M Q1 '24: -10.5M Q2 '24: -9.7M Q3 '24: -9.6M Q4 '24: -12.3M Q1 '25: -20.5M Q2 '25: -12.5M Q3 '25: -11.8M Q4 '25: -17.3M Q1 '26: -23.7M Q2 '26: -25.6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-30M -20M -10M 0 10M 20M 30M Q3 '21: -14.2M Q4 '21: -16.9M Q1 '22: -14M Q2 '22: -16.6M Q3 '22: -14.6M Q4 '22: -13.2M Q1 '23: -14.9M Q2 '23: -16M Q3 '23: -15.1M Q4 '23: -13.6M Q1 '24: -10.4M Q2 '24: -9.4M Q3 '24: -9.4M Q4 '24: -12.4M Q1 '25: -20.8M Q2 '25: -13M Q3 '25: -11.9M Q4 '25: -17.4M Q1 '26: -26.1M Q2 '26: -28.6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

0 15K 30K 45K Q1 '25: 0 Q2 '25: 0 Q1 '26: 14K Q2 '26: 32K Q1 '25 Q2 '25 Q1 '26 Q2 '26

Operating Cash Flow Quarterly

-24M -16M -8M 0 8M 16M 24M Q3 '21: -9.4M Q4 '21: -12.4M Q1 '22: -13.9M Q2 '22: -14.1M Q3 '22: -11.6M Q4 '22: -12.9M Q1 '23: -13.9M Q2 '23: -10.6M Q3 '23: -12.2M Q4 '23: -9.8M Q1 '24: -8.9M Q2 '24: -6.1M Q3 '24: -7M Q4 '24: -6.8M Q1 '25: -14M Q2 '25: -12.6M Q3 '25: -9.7M Q4 '25: -12.8M Q1 '26: -16.1M Q2 '26: -22.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-24M -16M -8M 0 8M 16M 24M Q1 '18: -4.7M Q2 '18: -3.4M Q3 '18: -5.6M Q4 '18: -7.3M Q3 '19: -8.6M Q4 '19: -16.7M Q3 '22: -11.7M Q4 '22: -13M Q1 '23: -13.9M Q2 '23: -10.6M Q3 '23: -12.2M Q4 '23: -9.8M Q3 '24: -7M Q4 '24: -6.9M Q1 '25: -14M Q2 '25: -12.6M Q3 '25: -9.8M Q4 '25: -13.1M Q1 '26: -16.1M Q2 '26: -22.7M Q2 '18 Q3 '19 Q4 '22 Q3 '23 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

EPS TTM

-1.50 -1.00 -0.50 0.00 0.50 1.00 1.50 Q3 '21: -0.75 Q4 '21: -1.02 Q1 '22: -1.05 Q2 '22: -1.46 Q3 '22: -1.46 Q4 '22: -1.37 Q1 '23: -1.39 Q2 '23: -1.37 Q3 '23: -1.38 Q4 '23: -1.39 Q1 '24: -1.25 Q2 '24: -1.02 Q3 '24: -0.81 Q4 '24: -0.68 Q1 '25: -0.78 Q2 '25: -0.84 Q3 '25: -0.82 Q4 '25: -0.78 Q1 '26: -0.67 Q2 '26: -0.68 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.